April 2026 Medtronic enrolled the first patient in the ENDURANCE post-approval study evaluating its Altaviva™ Tibial System for urge urinary incontinence treatment. The multicenter study is designed to evaluate long-term effectiveness and durability outcomes of the implantable tibial neuromodulation device, supporting further clinical adoption of advanced neuromodulation-based urinary incontinence therapies.
March 2026 Rohto Pharmaceutical expanded its medical device business into the Chinese market through the planned launch of a wearable neuromodulation device for managing overactive bladder symptoms. The company partnered with Australis Scientific Pty Ltd. and Beijing InnoStim Technology Co., Ltd. to introduce a non-invasive wearable solution integrated with an AI application for home-based bladder management.
January 2026 Wellspect HealthCare launched Surity™ Female External Catheter in the U.S. market, expanding its continence care portfolio with a non-invasive urinary incontinence management solution. The product was designed to support women living with severe urinary incontinence and provide an alternative approach for caregivers and patients requiring continence management solutions.
December 2025 BlueWind Medical received FDA 510(k) clearance for the Revi System, an implantable tibial electrical urinary continence device designed for patients with urgency incontinence. The system uses wireless-powered neuromodulation technology to stimulate the tibial nerve and provide a minimally invasive treatment option for urinary control disorders.